|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.57 AUD | -2.80% |
|
+1.32% | -8.94% |
| Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
| Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Clinuvel Pharmaceuticals Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported revenue was AUD 35.73 million compared to AUD 30.98 million a year ago. Net income was AUD 10.94 million compared to AUD 11.39 million a year ago.
Basic earnings per share from continuing operations was AUD 0.221 compared to AUD 0.23 a year ago. Diluted earnings per share from continuing operations was AUD 0.212 compared to AUD 0.22 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.94% | 476M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
CLINUVEL PHARMACEUTICALS LIMITED 
